Clinical trials
Cholecystitis, Acute trials with no applicable phase
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
70 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2008 | 1 |
| 2009 | 1 |
| 2011 | 1 |
| 2013 | 3 |
| 2015 | 2 |
| 2016 | 4 |
| 2017 | 5 |
| 2018 | 2 |
| 2019 | 9 |
| 2020 | 5 |
| 2021 | 3 |
| 2022 | 9 |
| 2023 | 3 |
| 2024 | 6 |
| 2025 | 7 |
| 2026 | 8 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 40 |
| Unknown status | 11 |
| Recruiting | 10 |
| Not yet recruiting | 5 |
| Terminated | 2 |
| Withdrawn | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Seoul St. Mary's Hospital | 4 |
| Assiut University | 3 |
| Medipol University | 3 |
| Chinese University of Hong Kong | 2 |
| Karolinska Institutet | 2 |
| Mansoura University | 2 |
| Sisli Hamidiye Etfal Training and Research Hospital | 2 |
| Yonsei University | 2 |
| Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 1 |
| Activ Surgical | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cholecystitis, Acute | 70 |
| Cholecystitis | 18 |
| Gallbladder Diseases | 8 |
| Gallstones | 6 |
| Cholelithiasis | 5 |
| Postoperative Pain | 5 |
| Bronchiolitis Obliterans Syndrome | 4 |
| Postoperative Complications | 3 |
| Choledocholithiasis | 2 |
| Postoperative Nausea and Vomiting | 2 |
Trials
Showing 26 to 50 of 70. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.